Cerebral blood volume estimation by ferumoxytol-enhanced steady-state MRI at 9.4 T reveals microvascular impact of α(1)-adrenergic receptor antibodies


  • A. Pohlmann
  • P. Karczewski
  • M.C. Ku
  • B. Dieringer
  • H. Waiczies
  • N. Wisbrun
  • S. Kox
  • I. Palatnik
  • H.M. Reimann
  • C. Eichhorn
  • S. Waiczies
  • P. Hempel
  • B. Lemke
  • T. Niendorf
  • M. Bimmler


  • NMR in Biomedicine


  • NMR Biomed 27 (9): 1085-1093


  • Cerebrovascular abnormality is frequently accompanied by cognitive dysfunctions, such as dementia. Antibodies against the alpha1-adrenoceptor (alpha1-AR) can be found in patients with Alzheimer's disease with cerebrovascular disease, and have been shown to affect the larger vessels of the brain in rodents. However, the impact of alpha1-AR antibodies on the cerebral vasculature remains unclear. In the present study, we established a neuroimaging method to measure the relative cerebral blood volume (rCBV) in small rodents with the ultimate goal to detect changes in blood vessel density and/or vessel size induced by alpha1-AR antibodies. For this purpose, mapping of R2 * and R2 was performed using MRI at 9.4 T, before and after the injection of intravascular iron oxide particles (ferumoxytol). The change in the transverse relaxation rates (DeltaR2 *, DeltaR2) showed a significant rCBV decrease in the cerebrum, cortex and hippocampus of rats (except hippocampal DeltaR2), which was more pronounced for DeltaR2 * than for DeltaR2. Immunohistological analyses confirmed that the alpha1-AR antibody induced blood vessel deficiencies. Our findings support the hypothesis that alpha1-AR antibodies lead to cerebral vessel damage throughout the brain, which can be monitored by MRI-derived rCBV, a non-invasive neuroimaging method. This demonstrates the value of rCBV estimation by ferumoxytol-enhanced MRI at 9.4 T, and further underlines the significance of this antibody in brain diseases involving vasculature impairments, such as dementia.